A new ADHD drug targets three brain chemicals instead of two. Here's what that means
A new medicine for attention-deficit/hyperactivity disorder (ADHD) has just entered the treatment toolbox: centanafadine, a once-daily tablet sold under the brand name Simtriyo.
A new ADHD medication called centanafadine has been developed, which works by targeting three brain chemicals - dopamine, norepinephrine, and serotonin - instead of the traditional two (dopamine and norepinephrine). This new approach offers a different mechanism of action from most existing ADHD treatments, which typically increase only dopamine and norepinephrine levels.
Centanafadine is the first of its kind to affect all three neurotransmitters, potentially providing a broader impact on brain function related to attention, hyperactivity and self-control.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
